MiMedx price target lowered to $12 from $15 at Mizuho

Mizuho lowered the firm’s price target on MiMedx (MDXG) to $12 from $15 and keeps an Outperform rating on the shares following the earnings report. The firm says coverage determination updates are the major catalysts for MiMedx, as “decreased spending on bad actors could confer share donation” to the company despite only 25% selling price exposure in the category.